To evaluate the expression of the Rho/Rho-associated protein kinase (ROCK) pathway in the corpus cavernosum of patients with severe erectile dysfunction (ED) compared with healthy human corpus cavernosum, and to test the functional effects of two Rho kinase inhibitors (RKIs) on erectile tissue of patients with severe ED, which did not respond to phosphodiesterase type 5 inhibitors (PDE5Is).
Objectives
To evaluate the expression of the Rho/Rho-associated protein kinase (ROCK) pathway in the corpus cavernosum of patients with severe erectile dysfunction (ED) compared with healthy human corpus cavernosum, and to test the functional effects of two Rho kinase inhibitors (RKIs) on erectile tissue of patients with severe ED, which did not respond to phosphodiesterase type 5 inhibitors (PDE5Is).
Patients and Methods
Human corpus cavernosum samples were obtained after consent from men undergoing penile prosthesis implantation (n = 7 for organ bath experiments, n = 17 for quantitative PCR [qPCR] ). Potent control subjects (n = 5) underwent penile needle biopsy. qPCR was performed for the expression of RhoA and ROCK subtypes 1 and 2. Immunohistochemistry staining against ROCK and a smooth muscle actin (aSMA) was performed on the corpus cavernosum of patients with ED. Tissue strips were precontracted with phenylephrine and incubated with 1 lM of the PDE5I vardenafil or with DMSO (control). Subsequently, increasing concentrations of the RKIs azaindole or Y-27632 were added, and relaxation of tissue was quantified.
Results
The expression of ROCK1 was unchanged (P > 0.05), while ROCK2 (P < 0.05) was significantly upregulated in patients with ED compared with controls. ROCK1 and ROCK2 protein colocalized with aSMA, confirming the presence of this kinase in cavernous smooth muscle cells and/or myofibroblasts. After incubation with DMSO, 10 lM azaindole and 10 lM Y-27632 relaxed precontracted tissues with 49.5 AE 7.42% (P = 0.1470 when compared with vehicle) and 85.9 AE 10.3% (P = 0.0016 when compared with vehicle), respectively. Additive effects on relaxation of human corpus cavernosum were seen after preincubation with 1 lM vardenafil.
Introduction
Erectile dysfunction (ED) is a condition in which patients are unable to attain or maintain an erection sufficient for sexual intercourse. The first-line pharmacotherapeutic strategy for ED consists of phosphodiesterase type 5 inhibitors (PDE5Is), for which the overall efficacy rate is 60-70% [1] . Specific patients in whom PDE5Is have reduced efficacy are patients who have undergone radical prostatectomy, and those with diabetes, as these conditions are marked by a decreased nitric oxide (NO) release from the cavernous nerves and endothelium, and PDE5Is depend on an intact NO supply to be efficacious [2] . Because such patients currently have to resort to intracavernous injections of vaso-active agents or penile prosthesis implantation, interest in alternative oral pharmacotherapeutical strategies has grown in recent years [3, 4] .
One of the pathways that has been heavily investigated is the Rho-associated protein kinase (ROCK) system. RhoA is a monomeric GTP-binding protein that activates Rho kinase [5] . ROCK1 and ROCK2 act on a large set of substrates and thereby induce multiple cellular responses. One of these substrates is myosin phosphatase target subunit 1 (MYPT1; a regulatory subunit of myosin light chain phosphatase), which, when phosphorylated, results in increased myosin light chain phosphorylation and which facilitates the interaction between myosin and actin. It hereby causes Ca2+-sensitization of the contractile proteins, enhancing smooth muscle contraction [6] ; therefore, the ROCK system seems to play an important role in maintaining cavernous smooth muscle tone in the flaccid state, and activation or overexpression of this cascade results in smooth muscle hypercontractility. Rho-kinase inhibitors (RKIs) could thus be useful for reversal of this mechanism to achieve relaxation of cavernosal smooth muscle, independent of nitric oxide supply [4] . Other targets include kinase C-potentiated phosphatase inhibitor of 17 kDa (CPI-17) and myosin II regulatory light chain, which, like MYPT1, are also associated with smooth muscle contraction, as well as LIM-kinase 1 and 2 (LIMK1/2), phosphatase and tensin homologue deleted on chromosome 10 (PTEN), formin homology 2 domain-containing 1 (FHOD1) and ezrin-radixin-moesin (ERM) associated with F-actin stabilization, inhibition of vascular smooth muscle cell proliferation, intermediate filament disruption and actinmembrane linkage, respectively [7] .
In different animal models of ED, an upregulation of the ROCK pathway in the corpus cavernosum has been observed, while inhibition of this pathway with RKIs facilitated penile erection. Indeed, Jin et al. [8] showed an upregulation of membrane-bound RhoA in aged rats with ED, Bivalacqua et al. [9] described an upregulation of the ROCK pathway in diabetic rats with ED, and Gratzke et al. [10] noted an upregulation of the ROCK pathway in rats which underwent bilateral cavernous nerve injury as a rat model for postradical prostatectomy ED.
While RKIs have been tested in early development phases in patients with ED, the profound upregulation of the ROCK system that was observed in small animal models for ED was never confirmed in humans; therefore, the aim of the present study was to test the expression of ROCK mRNA in the corpus cavernosum of patients with ED compared to healthy human corpus cavernosum, and to test the functional effects of two RKIs (azaindole and Y-27632), alone or in combination with vardenafil, on the erectile tissue of patients with severe ED not responding to PDE5I treatment.
Patients and Methods

Experimental Design
Human corpus cavernosum samples were obtained from 21 patients with ED of various aetiology, who underwent inflatable penile prosthesis (IPP) implantation because of failure of PDE5I therapy (n = 7 for contractility experiments, n = 17 for quantitative PCR [qPCR]). All patients were offered intracavernosal injections of prostaglandin E1 before considering IPP implantation. Control tissue was harvested by corpus cavernosum needle biopsy taken at the distal third of the penile shaft (16 G; Tru-Cut Biopsy Needle, Becton-Dickinson, Erembodegem, Belgium) from consenting age-matched donors without ED (International Index of Erectile Function Questionnaire -Erectile Function score >25) who underwent transurethral resection of prostate adenomas in the setting of acute urinary retention (n = 5); therefore, none of these patients was treated with 5-a-reductase inhibitors at the time of tissue harvesting. Patients and age-matched controls (P = 0.25 for age) consented to the use of penile tissues, and the study protocol was approved by the ethical review board at Jessa Hospital, Hasselt, Belgium and the Biobank Limburg, Hasselt, Belgium. The study thereby complied with international regulations for protection of patients. Control tissues from needle biopsies were snap-frozen and used for qPCR analysis because of the size limit of the tissue. Patient characteristics and risk factors for ED are summarized in Table 1 .
Quantitative PCR
Real-time qPCR was used to identify expression of various components in the ROCK system in human corpus cavernosum of patients and age-matched healthy controls. Total RNA was isolated using RNeasy mini columns (Qiagen S.A., Courtaboeuf, France) and further purified by Dnase digestion. The mRNA expression of ROCK1, ROCK2 and b-actin was measured using real-time qPCR (TaqMan-PCR) with an ABI Prism 7700 sequence detection instrument (Applied Biosystems, Inc., Carlsbad, CA, USA). In brief, 1 lg of total RNA was transcribed into cDNA with a Superscript II RT cDNA synthesis kit (Gibco, Inc., Carlsbad, CA, USA). Normalization of the cycle threshold data was carried out to the reference gene b-actin.
Immunofluorescence Microscopy
Immunohistochemistry staining against ROCK subtypes 1 and 2 and a smooth muscle actin (aSMA) was performed on the 326 © 2016 The Authors BJU International © 2016 BJU International corpus cavernosum of patients with ED. Samples were fixed in 10% neutral-buffered formalin and embedded in paraffin. Paraffin sections were dewaxed in xylene and rehydrated with a graded ethanol series. Slides were washed in TBS. For epitope retrieval, slides were exposed in citrate buffer (pH 6) and heated to~90°C for 60 min. After washing in TBS, the slides were blocked for 60 min using BSA 1%, NGS 3%, Triton X-100 0.3% in PBS (Sigma-Aldrich, St. Louis, MO, USA), followed by incubation overnight at 4°C in a humidified chamber with 1/200 Rb ROCK1, 1/200 Rb anti-ROCK2 (Abcam, Cambridge, UK) and 1/200 Ms anti-smooth muscle actin (Dako, Copenhagen, Denmark). Slides were then rinsed in PBS, incubated for 1 h at 20 to 22°C with secondary antibodies 1/500 Alexa Fluor 594 donkey anti-mouse, 1/500 Alexa Fluor 488 donkey anti-rabbit (Invitrogen, Carlsbad, CA, USA) as secondary antibodies. Control staining in the absence of primary antibodies was used to evaluate non-specific staining by secondary antibodies. Nuclear staining was performed using 4 0 ,6-diamidino-2-phenylindole or DAPI (Invitrogen). Slides were evaluated and photographed using an Olympus microscope (Olympus, Tokyo, Japan).
Isometric Tension Measurement in in vitro Studies
Immediately after harvesting the samples during IPP implantation, they were immersed in ice-cold Krebs-Henseleit solution (in mmol/L: NaCl 112, KCl 5.9, CaCl 2 2.0 MgCl 2 1.2, NaH 2 PO 4 1.2, NaHCO 3 25, glucose 11.5) and transported. The samples were divided into six equally sized longitudinal strips of~2 9 5 mm. These strips were then transferred into organ baths of 45 mL Krebs-Henseleit solution at 37°C equilibrated with 95% O 2 , 5% CO 2 . Strips were mounted between two clips, which were in turn attached at one side to a fixed glass bar and on a force transducer. The height of the force transducer was adjustable to be able to give a precise preload to the mounted tissue strips. The force transducer was connected to an amplifier and a laptop with chart recording software (LabChart). The mounting was followed by a 60-min equilibration period, in which a preload tension was fixed at 3 g. Every 10 min, the tension was adjusted to maintain the preload of 3 g. After the equilibration period, the strips were precontracted with 10 lmol/L phenylephrine. Ten minutes after precontraction, the baths were washed out twice. This was repeated once more, after which the tissue was precontracted a third time with 10 lmol/L phenylephrine. The maximum tension after this precontraction was defined as 100% tension. After stabilization of the tension traces, 1 lM vardenafil or vehicle (DMSO) was added. Subsequently, increasing concentrations of azaindole or Y-27632 were added (range 10 -9 to 10 -5 M).
Statistical Analysis
All values are expressed as mean AE SEM. Statistical differences were determined by a Student's t-test or Mann-Whitney test, depending on normality of the data. A P value of <0.05 was considered to indicate a statistically significant difference.
Results
Quantitative PCR
To investigate the regulation of the ROCK system in patients with ED and failure of PDE5I therapy, we harvested needle biopsies from control subjects without ED as a comparison. Quantitative evaluation showed that the expression of ROCK1 was unchanged (P > 0.05), while ROCK2 (relative expression: 7 570 AE 3 013 vs 2 924 AE 432; P < 0.05) was significantly upregulated in patients with ED. These data are shown in Figs 1 and 2 . The expression of aSMA was higher in the corpus cavernosum from patients with ED (relative expression 504 243 AE 15 265 vs 385 483 AE 25 456; P < 0.05). Overall cellular content was similar, as illustrated by similar cycle threshold values for b-actin (data not shown).
Immunofluorescence Microscopy
Using immunofluorescence microscopy, we noted that ROCK protein subtypes 1 and 2 colocalized with aSMA, confirming the presence of this kinase in cavernous smooth muscle cells lining the sinusoids of the penis (Figs 1 and 2 ). Immunofluorescence could not be conducted on control tissue because of small sample sizes.
Isometric Tension Measurement in in vitro Studies
The relaxant capacity of RKIs and vardenafil on human corpus cavernosum was tested in organ bath experiments (Figs 3 and 4) . After pre-incubation with DMSO, 10 lM azaindole and 10 lM Y-27632 relaxed precontracted tissues by 49.5 AE 7.42% (P = 0.147 when compared with vehicle) and 85.9 AE 10.3% (P = 0.002 when compared with vehicle), respectively.
Added effects on relaxation of human corpus cavernosum were seen after pre-incubation with 1 lM vardenafil, which relaxed precontracted tissues with 24.4 AE 19.3%. Indeed, after pre-incubation with 1 lM vardenafil, 10 lM azaindole and 10 lM Y-27632 relaxed precontracted tissues by an additional 40.8 AE 5.52% (P = 0.2) and 73.6 AE 18.7% (P = 0.048) respectively, when compared with vehicle.
Discussion
Erectile dysfunction is highly prevalent, with 5-20% of the male population having moderate to severe ED. Currently, the treatment is based on PDE5 inhibition [11] . Although many patients benefit from PDE5Is, drop-out rates of >50% have been reported, with lack of efficacy as the most important reason [12] . Possibly, the persistent need for endogenous NO production plays an important role in the failure of PDE5Is, especially in disease states in which NO bioavailability is impaired. Interest in strategies to regulate the cavernosal smooth muscle tone without a need for endogenous NO production has therefore grown significantly in recent years [2] . GTP-binding protein RhoA. There are two isoforms of Rhokinase, namely ROCK1 and ROCK2. ROCK1 has a ubiquitous tissue distribution, while ROCK2 is mostly present in neural and muscular tissues, and has been extensively characterized in vascular smooth muscle cells [13] . Their crucial role in a variety of cellular functions, such as proliferation, apoptosis, contraction, fibrosis, endothelial cell dysfunction and cardiomyocyte dysfunction has been frequently reported. Rho-kinases have therefore been implicated in the pathophysiology of hypertension, stroke, arteriosclerosis, pulmonary arterial hypertension, vasospastic angina, diabetes, cardiac ischaemia/reperfusion injury and heart failure, which rendered them important pharmacotherapeutical targets [13] . Interestingly, the RKI fasudil has been found to be efficient in preventing coronary vasospasm [14] , in the treatment of microvascular angina [15] , and in ameliorating the exercise tolerance of patients with stable effort angina [16] . Also, fasudil and Y-27632 have been shown to be useful in the reversal of established fibrosis and have been suggested as a powerful treatment in the reversal of pulmonary arterial hypertension [17] . The ROCK1/2 pathway might therefore be a promising target for reversal of ED.
Unlike other smooth-muscle types in which the contractile state varies more frequently, penile smooth muscle remains tonically contracted to maintain the flaccid state of the penis, unless NO is released and these effects are outweighted by the pro-relaxant, including the cGMP/protein kinase (cGMP-PKG) pathway [3] . If NO bioavailability is reduced by certain diseases such as diabetes and neural injury (vide supra), corpus cavernosum smooth muscle is rendered into a hypercontractile state. This state becomes even more pronounced when the ROCK pathway is activated or overexpressed, as has been shown in various animal models for ED. Suprisingly, in humans it has never been shown that corpus cavernosum ROCK upregulation is prevalent in ED. In the present study we provide the first evidence that specifically ROCK2 is overexpressed in corpus cavernosum smooth muscle in the presence of severe ED. Targeting the ROCK pathway, therefore, in the search for new therapeutic targets and strategies for ED is a logical step and, in different animal models of ED and in vitro studies, it has been shown that inhibition of ROCK results in relaxation of corporeal smooth muscle and potentiation of erection [8] [9] [10] . In their seminal paper, Chitaley et al. [18] showed that Rho-kinase antagonism by injection of Y-27632 stimulates rat penile erection independently of NO in healthy rats and strongly potentiated nerve-stimulation-induced erectile activity. Later, administration of the Rho-kinase inhibitor Y-27632 or antagonisation of the ROCK system by gene therapy improved erectile function in diseased (diabetes or cavernous nerve injury) or aged rats. Furthermore, the effect of Y-27632 on erectile responses was found to be dose-dependent [8] . Besides acute effects, chronic administration of RKIs has been shown to preserve erectile function after cavernous nerve injury by reduction of apoptosis of cavernous smooth muscle [19] , and in diabetic animals similarly by upregulating antiapoptotic pathways in the penile innervation [9] . Also, additive effects of RKIs and PDE5I have been reported in several animal models. Rajasekaran et al. [20] showed there was a synergistic effect on the erectile response in old rats after intracavernosal administration of Y-27632 and a PDE5I, compared with the administration of Y-27632 alone. Furthermore, Wilkes et al. [21] investigated the effect of Rho kinase inhibition in hypertensive rats. The erectile response improved significantly and immediately after intracavernosal injection of Y-27632. An intracavernosal injection of PDE5I followed by Y-27632 resulted in a synergistic improvement of the erectile response [21] .
Surprisingly, the possible biological and therapeutic importance of this pathway in humans has been investigated and described only sparsely. In the present study, we found that the expression of ROCK1 in the corpus cavernosum tissue of patients with ED was unchanged when compared with healthy controls, while ROCK2 expression was significantly upregulated. Immunohistochemistry showed that ROCK colocalized with aSMA, which confirms the presence of this kinase in human cavernous smooth muscle cells. Furthermore, we were able to confirm the previous findings of Guagnini et al. [22] that Rho-kinase inhibitors relax corpus cavernosum strips of patients with ED, not responding to PDE5Is [22] . After incubation with DMSO, azaindole and Y-27632 relaxed the precontracted human tissues. Finally, we describe for the first time additive effects of a combination of PDE5I with RKIs in humans. Indeed, the combination of Y-27632 and vardenafil was significantly more effective in relaxing precontracted human corpus cavernosum strips than vardenafil alone. This finding shows that RKIs increase responsiveness to PDE5I and thus may become a valid treatment option to rescue difficult to treat patients with ED with an orally available medication. The expression on ROCK2 in the vascular smooth muscle may indicate that RKIs cause decreases in vascular tone and thus in systemic blood pressure; lowering the dose of RKI and adding a PDE5I potentially reduces systemic side effects and enhances local effects resulting from preferential expression of PDE5A in the cavernous smooth muscle [3] . It must be noted that promising in vitro results do not always result in the therapeutic use of drugs. For example, the concentration needed to achieve in vivo effects may be so high that adverse effects occur before the desired effect takes place. There is, however, some experience in humans of good tolerance of the use of RKIs. Knipe et al. [17] revised past experience with the systemic use of fasudil in a recent article. Fasudil is an RKI that has been used in humans to reduce cerebral vasospasm and stable angina. For both indications, fasudil was found to be effective and well tolerated. Thus, even though clinical experience with RKIs is limited, they are a rational target for therapeutic use in ED.
The present study has some limitations. Because of ethical restrictions, it was not possible to harvest corpus cavernosum samples in control patients without ED that would allow us to do organ bath experiments. For the same reason, no quantitative differences in protein level could be evaluated. Also, direct assessment of the ROCK2 protein concentration and kinase activity was not performed, as qPCR only assesses mRNA expression. Further studies are therefore needed to confirm an upregulation of ROCK2 protein and kinase activity. Ultimately, selective ROCK2 inhibition was not tested. Indeed, the ROCK2-selective kinase inhibitor KD025 was found to have good efficacy and a favourable safety profile when tested as a therapy for cerebral ischaemia in mice [23] . Future studies are needed to assess if ROCK2-selective kinase inhibitors are applicable in the treatment of ED, as fewer side effects are to be expected with selective inhibition.
The present findings indicate, however, that RKIs may become a valid treatment option to help patients with difficult-to-treat ED with an orally available medication.
We can conclude that the Rho-kinase inhibitor Y-27632 causes a significant relaxation of corpus cavernosum in tissue strips of patients with severe erectile dysfunction. The additive effect of vardenafil and Y-27632 show that a combined inhibition of Rho-kinase and PDE5 could be a promising orally administered treatment for severe ED.
